« Welcome! | Main | Running For Ramona »
June 26, 2003
Prestwick Snags $15 Million
Prestwick Pharmaceuticals announced that they've secured $15 million in financing. In their press release was this little tidbit:
"Prestwick has several product candidates in clinical development. Its lead product is Xenazine, a molecule that has been approved to treat Huntington's chorea in Europe, Canada, and Australia, but has not yet been approved in the U.S. Xenazine's effectiveness in chorea has been shown in multiple published clinical studies, and there is currently no approved therapeutic product in the U.S. for this indication. Xenazine is undergoing pivotal Phase III clinical testing in the U.S., and the company hopes to file an NDA in the near future. " Read the full Press Release here.
Xenazine is not a 'cure', it is used to calm down movement (chorea). It looks like it has some significant side effects and, should it be approved, may not be suitable for everybody. If approved, we could see it in the US within a year or two.
Posted by Dave at June 26, 2003 10:42 PM
Trackback Pings
TrackBack URL for this entry:
http://www.huntingtons.info/MT/mt-tb.cgi/2
Comments
Post a comment
Thanks for signing in, . Now you can comment. (sign out)
(If you haven't left a comment here before, you may need to be approved by the site owner before your comment will appear. Until then, it won't appear on the entry. Thanks for waiting.)